Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | HCN1 | O60741 | 7/20 | 0.50 |
| ▸ | HCN4 | Q9Y3Q4 | 8/20 | 0.49 |
| ▸ | TP53 | P04637 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | THRB | P10828 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2428429 | 0.76 | SIGMAR1 (0.47) | OPRM1SIGMAR1HCN1HCN4TP53 | |
| SCHEMBL2427617 | 0.72 | MEN1 (0.45) | TP53LMNAMEN1KMT2A | |
| SCHEMBL2428426 | 0.71 | SIGMAR1 (0.46) | OPRM1SIGMAR1HCN1HCN4TP53 | |
| SCHEMBL2433928 | 0.71 | SIGMAR1 (0.48) | OPRM1SIGMAR1HCN1HCN4TP53 | |
| SCHEMBL18426940 | 0.68 | OPRM1 (0.53) | OPRM1SIGMAR1HCN1HCN4MEN1 | |
| SCHEMBL31620120 | 0.66 | HSD17B3 (0.33) | — | |
| SCHEMBL5475938 | 0.64 | HSD17B3 (0.31) | — | |
| SCHEMBL14376425 | 0.62 | HCN1 (0.46) | OPRM1SIGMAR1HCN1HCN4TP53 | |
| SCHEMBL4374590 | 0.62 | TP53 (0.58) | OPRM1SIGMAR1HCN1HCN4TP53 | |
| SCHEMBL16233192 | 0.62 | TP53 (0.73) | OPRM1SIGMAR1HCN1HCN4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212946-A1 | Quinolone Neuropeptide S Receptor Antagonists | MERCK SHARP & DOHME LLC | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212946-A1 | Quinolone Neuropeptide S Receptor Antagonists | NPSR1, NPY1R, NPY2R | OPRM1 145/4885SIGMAR1 194/4885HCN1 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.